Chiesi Farmaceutici, R&D Department, Parma, Italy.
Department of Veterinary Science, University of Parma, Parma, Italy.
PLoS One. 2018 Jul 12;13(7):e0200542. doi: 10.1371/journal.pone.0200542. eCollection 2018.
Nasal intermittent positive pressure ventilation (NIPPV) holds great potential as a primary ventilation support method for Respiratory Distress Syndrome (RDS). The use of NIPPV may also be of great value combined with minimally invasive surfactant delivery. Our aim was to implement an in vivo model of RDS, which can be managed with different non-invasive ventilation (NIV) strategies, including non-synchronized NIPPV, synchronized NIPPV (SNIPPV), and nasal continuous positive airway pressure (NCPAP). Forty-two surfactant-depleted adult rabbits were allocated in six different groups: three groups of animals were treated with only NIV for three hours (NIPPV, SNIPPV, and NCPAP groups), while three other groups were treated with surfactant (SF) followed by NIV (NIPPV+SF, SNIPPV+SF, and NCPAP+SF groups). Arterial gas exchange, ventilation indices, and dynamic compliance were assessed. Post-mortem the lungs were sampled for histological evaluation. Surfactant depletion was successfully achieved by repeated broncho-alveolar lavages (BALs). After BALs, all animals developed a moderate respiratory distress, which could not be reverted by merely applying NIV. Conversely, surfactant administration followed by NIV induced a rapid improvement of arterial oxygenation in all surfactant-treated groups. Breath synchronization was associated with a significantly better response in terms of gas exchange and dynamic compliance compared to non-synchronized NIPPV, showing also the lowest injury scores after histological assessment. The proposed in vivo model of surfactant deficiency was successfully managed with NCPAP, NIPPV, or SNIPPV; this model resembles a moderate respiratory distress and it is suitable for the preclinical testing of less invasive surfactant administration techniques.
鼻内间歇正压通气(NIPPV)作为呼吸窘迫综合征(RDS)的主要通气支持方法具有很大的潜力。NIPPV 与微创表面活性剂输送联合使用也可能具有很大的价值。我们的目的是建立一种 RDS 的体内模型,可以通过不同的无创通气(NIV)策略进行管理,包括非同步 NIPPV、同步 NIPPV(SNIPPV)和鼻持续气道正压通气(NCPAP)。42 只去表面活性物质的成年兔被分配到六个不同的组:三组动物仅接受 NIV 治疗 3 小时(NIPPV、SNIPPV 和 NCPAP 组),而另外三组接受表面活性剂(SF)治疗后再接受 NIV(NIPPV+SF、SNIPPV+SF 和 NCPAP+SF 组)。评估动脉血气交换、通气指数和动态顺应性。死后取肺进行组织学评估。通过重复支气管肺泡灌洗(BAL)成功实现了表面活性剂耗竭。BAL 后,所有动物均出现中度呼吸窘迫,仅应用 NIV 无法逆转。相反,表面活性剂给药后再行 NIV 可使所有接受表面活性剂治疗的组的动脉氧合迅速改善。与非同步 NIPPV 相比,呼吸同步与气体交换和动态顺应性的改善显著相关,在组织学评估后显示出最低的损伤评分。用 NCPAP、NIPPV 或 SNIPPV 成功管理了拟议的去表面活性物质缺乏的体内模型;该模型类似于中度呼吸窘迫,适合于微创表面活性剂给药技术的临床前测试。